Jourdan Jean-Pierre, Muzard Alexandra, Goyer Isabelle, Ollivier Yann, Oulkhouir Youssef, Henri Patrick, Parienti Jean-Jacques, Breuil Cécile
Department of Pharmacy, Caen UHC, 14000, Caen, France.
Centre d'Etudes et de Recherche sur le Médicament de Normandie, Normandie University, UNICAEN, CERMN, 14000, Caen, France.
Int J Clin Pharm. 2018 Dec;40(6):1474-1481. doi: 10.1007/s11096-018-0733-6. Epub 2018 Oct 26.
Background A significant number of clinical pharmacy services have shown to improve in-hospital medication safety and patient outcome. Prescription review and pharmacist interventions are a fundamental part of hospital clinical pharmacy activities. In a context of restricted financial resources, proving the economic and clinical impact of this activity seems necessary. Objective The aim of this study was to assess the clinical impact on patient outcomes and economic benefit of prescription review by pharmacists. Setting 1624-bed tertiary French university teaching hospital. Method Prospective single center study evaluating prescriptions for which a pharmacist intervention was issued over a 6-month period. The clinical impact of every pharmacist intervention was evaluated by a multidisciplinary experts committee. Economic benefit was evaluated from the public health care system spending standpoint. Main outcome measures Number of avoided hospitalization days and associated public health care system cost-avoidance. Results Prescription review and interventions by pharmacists prevented 73 intensive care unit hospitalization days, 74 continuous monitoring unit hospitalization days and 66 days of conventional hospitalization. €252,294.00 in public health expenditure were thus prevented. For every Euro invested in the prescription review activity, €5.09 of public health spending were potentially saved. Conclusion Our study shows that prescription review and clinical pharmacists' interventions had an impact on clinical outcomes which translated into prevented hospitalization days. Prescription optimization through pharmacist interventions allows significant health care cost savings which makes this service highly efficient.
大量临床药学服务已被证明可改善住院用药安全性和患者预后。处方审核和药师干预是医院临床药学活动的基本组成部分。在财政资源有限的情况下,证明这项活动的经济和临床影响似乎很有必要。
本研究旨在评估药师进行处方审核对患者预后的临床影响和经济效益。
拥有1624张床位的法国三级大学教学医院。
前瞻性单中心研究,评估在6个月期间发布了药师干预措施的处方。每项药师干预的临床影响由多学科专家委员会评估。从公共医疗保健系统支出的角度评估经济效益。
避免的住院天数及相关的公共医疗保健系统成本避免情况。
药师进行的处方审核和干预预防了73天重症监护病房住院、74天持续监测病房住院以及66天常规住院。从而避免了252,294.00欧元的公共卫生支出。在处方审核活动中每投入1欧元,就可能节省5.09欧元的公共卫生支出。
我们的研究表明,处方审核和临床药师干预对临床结局有影响,表现为避免了住院天数。通过药师干预实现处方优化可大幅节省医疗保健成本,这使得这项服务非常高效。